[
  {
    "ts": null,
    "headline": "BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline",
    "summary": "BeOne Medicines AG earns Strong Buy rating as BRUKINSA drives growth and pipeline advances. Click here to find out why ONC stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=1d0a10d7b2e0517437c35b3be268caa7f050c7759cf82bca9da541ff8ce92d5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760459078,
      "headline": "BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline",
      "id": 137087730,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2236028398/image_2236028398.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BeOne Medicines AG earns Strong Buy rating as BRUKINSA drives growth and pipeline advances. Click here to find out why ONC stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=1d0a10d7b2e0517437c35b3be268caa7f050c7759cf82bca9da541ff8ce92d5d"
    }
  },
  {
    "ts": null,
    "headline": "Kailera nets $600m to power Phase III launch of obesity drug",
    "summary": "Weight loss treatment-focused biotechs are bucking the wider downturn in early-stage investments.",
    "url": "https://finnhub.io/api/news?id=6c206f0365765873436dfb71843d2f65cb738f7fa29de03ee82a3c5c70586ea4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760457743,
      "headline": "Kailera nets $600m to power Phase III launch of obesity drug",
      "id": 137085505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weight loss treatment-focused biotechs are bucking the wider downturn in early-stage investments.",
      "url": "https://finnhub.io/api/news?id=6c206f0365765873436dfb71843d2f65cb738f7fa29de03ee82a3c5c70586ea4"
    }
  },
  {
    "ts": null,
    "headline": "Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?",
    "summary": "ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.",
    "url": "https://finnhub.io/api/news?id=6a8b7af46b3d6cfb0ab5527d9dc920b0d4a2f26f7e6667e176ab5929df99e608",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760454540,
      "headline": "Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?",
      "id": 137085506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.",
      "url": "https://finnhub.io/api/news?id=6a8b7af46b3d6cfb0ab5527d9dc920b0d4a2f26f7e6667e176ab5929df99e608"
    }
  },
  {
    "ts": null,
    "headline": "Kailera nets $600M more to advance Zepbound-like obesity drug",
    "summary": "Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.",
    "url": "https://finnhub.io/api/news?id=8f4deef4a4afd6bcde327836d0aa738c9a90eaac637cb12d2689ccc9d6aadd64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760442300,
      "headline": "Kailera nets $600M more to advance Zepbound-like obesity drug",
      "id": 137085507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.",
      "url": "https://finnhub.io/api/news?id=8f4deef4a4afd6bcde327836d0aa738c9a90eaac637cb12d2689ccc9d6aadd64"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa",
    "summary": "Strong sector performers stand out as AAPL, LLY, and V gain traction through services, drug demand, and digital payment growth.",
    "url": "https://finnhub.io/api/news?id=3dd10953ee6e8fb9fa318e9bee8c356c437da1c6ea99c976645273dee63d2437",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760431080,
      "headline": "The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa",
      "id": 137085364,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Strong sector performers stand out as AAPL, LLY, and V gain traction through services, drug demand, and digital payment growth.",
      "url": "https://finnhub.io/api/news?id=3dd10953ee6e8fb9fa318e9bee8c356c437da1c6ea99c976645273dee63d2437"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Papa John's Delivers A Hot Slice",
    "summary": "Papa John's soars after report of takeover offer. Roche, Eli Lilly Alzheimer's blood diagnostic test wins FDA approval. Japanese payment app PayPay valuation to likely exceed $20B in US IPO.",
    "url": "https://finnhub.io/api/news?id=ff3ece167b6147e78977502ea27f225e01cd89dc40999deb0e17d5ce282f1f81",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760428140,
      "headline": "Wall Street Breakfast Podcast: Papa John's Delivers A Hot Slice",
      "id": 137076200,
      "image": "https://static3.seekingalpha.com/assets/podcasts/wsb-d57bf915fd82bac19817953c2e226c7610de9fc3a36c166d7c276e18e86311ea.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Papa John's soars after report of takeover offer. Roche, Eli Lilly Alzheimer's blood diagnostic test wins FDA approval. Japanese payment app PayPay valuation to likely exceed $20B in US IPO.",
      "url": "https://finnhub.io/api/news?id=ff3ece167b6147e78977502ea27f225e01cd89dc40999deb0e17d5ce282f1f81"
    }
  }
]